Form D · Biotechnology
Ceretype Neuromedicine, Inc.
Cambridge, MA · CIK 0001884863
Offering snapshot reported Dec 18, 2025 · SEC filing
- Reported sold
- $400K Offering amount: $400K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 6, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 18, 2025 | Initial | $400,000 | No comparison | 3 | SEC filing |
| Nov 22, 2021 | Initial | $1,375,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-567252
Source: Form D, filed Dec 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Lipkin | Director |
| Hong Pan | Director |
| David Silbersweig | Director |
| Emily Stern | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Broadway, 14th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142